Luboshitzky R, Lavi S, Thuma I, Lavie P
Endocrine Institute, Central Emek Hospital, Afula, Israel.
J Clin Endocrinol Metab. 1996 Feb;81(2):770-4. doi: 10.1210/jcem.81.2.8636302.
Recently, we demonstrated that melatonin secretion is increased in untreated male patients with GnRH deficiency. As testosterone (T) can be aromatized to estradiol (E2), and both T and E2 increase during T enanthate treatment, we were interested in determining whether T treatment (when T and E2 levels were well matched with pubertal control values) has an effect on melatonin levels in these patients. We measured nocturnal serum melatonin levels during the administration of 250 mg testosterone enantale/month for 4 months in 12 male patients with idiopathic hypogonadotropic hypogonadism (IGD; n = 6) and delayed puberty (DP; n = 6). Serum samples for melatonin and LH determinations were obtained every 15 min from 1900-0700 h in a controlled light-dark environment. The results of melatonin profiles were compared with the pretreatment values in each group and with values obtained in six normal pubertal male controls. After 4 months of testosterone treatment, all patients attained normal serum testosterone (19.5 +/- 3.7 in IGD vs. 20.8 +/- 4.1 nmol/L in DP) and E2 levels (83 +/- 12 in IGD vs. 84 +/- 9 pmol/L in DP). Serum LH levels were suppressed in all patients during T treatment (0.12 +/- 0.1 in IGD vs. 0.12 +/- 0.2 IU/L in DP). Before T treatment, patient melatonin levels were greater than those in age-matched pubertal controls. Melatonin levels were equal in patients and controls when T and E2 levels were well matched. Mean (+/- SD) dark-time melatonin levels decreased from 286 +/- 23 to 157 +/- 36 pmol/L in IGD and from 217 +/- 32 to 133 +/- 47 pmol/L in DP (vs. 183 +/- 64 pmol/L in controls). The integrated melatonin values decreased to normal (from 184 +/- 16 to 102 +/- 21 in IGD and from 142 +/- 19 to 90 +/- 26 pmol/min.L x 10(3) in DP vs. 119 +/- 61 pmol/min.L x 10(3) in controls). The intraindividual variations in melatonin levels ranged from 7.2-14.5%. These data indicate that male patients with GnRH deficiency have increased nocturnal melatonin secretion. T treatment decreased melatonin secretion to normal levels. The results suggest that in GnRH-deficient male patients, sex steroids, rather than LH, modulate pineal melatonin in a reverse fashion.
最近,我们证明了在未经治疗的促性腺激素释放激素(GnRH)缺乏男性患者中,褪黑素分泌增加。由于睾酮(T)可被芳香化为雌二醇(E2),且在庚酸睾酮治疗期间T和E2均升高,我们有兴趣确定T治疗(当T和E2水平与青春期对照值良好匹配时)是否对这些患者的褪黑素水平有影响。我们在12名特发性低促性腺激素性性腺功能减退(IGD;n = 6)和青春期延迟(DP;n = 6)的男性患者中,测量了每月给予250 mg庚酸睾酮,持续4个月期间的夜间血清褪黑素水平。在可控的明暗环境中,于19:00至07:00每15分钟采集一次用于测定褪黑素和促黄体生成素(LH)的血清样本。将褪黑素水平的结果与每组的治疗前值以及在6名正常青春期男性对照中获得的值进行比较。经过4个月的睾酮治疗后,所有患者的血清睾酮水平均达到正常(IGD组为19.5±3.7,DP组为20.8±4.1 nmol/L)以及E2水平(IGD组为83±12,DP组为84±9 pmol/L)。在T治疗期间,所有患者的血清LH水平均受到抑制(IGD组为0.12±0.1,DP组为0.12±0.2 IU/L)。在T治疗前,患者的褪黑素水平高于年龄匹配的青春期对照。当T和E2水平良好匹配时,患者和对照的褪黑素水平相等。IGD组平均(±标准差)夜间褪黑素水平从286±23降至157±36 pmol/L,DP组从217±32降至133±47 pmol/L(对照组为183±64 pmol/L)。褪黑素积分值降至正常(IGD组从184±16降至102±21,DP组从142±19降至90±26 pmol/min·L×10³,对照组为119±61 pmol/min·L×10³)。褪黑素水平的个体内变异范围为7.2 - 14.5%。这些数据表明,GnRH缺乏的男性患者夜间褪黑素分泌增加。T治疗使褪黑素分泌降至正常水平。结果提示,在GnRH缺乏的男性患者中,性类固醇而非LH以相反的方式调节松果体褪黑素。